DLL3 and small cell lung carcinoma: As such, taking consideration of the mechanism of variable expression and the pathway of DLL3 in SCLC, targeting DLL3 as a selective therapeutic for SCLC emerged as a new direction in the current research field, and the development and assessment of DLL3-specific targeted SCLC therapeutics are being sought following by the researchers (Table 2).